Quick Hits

The advent of direct acting antivirals (DAAs) in the treatment of chronic hepatitis C infection has been revolutionary in that they have drastically mitigated the side effects of therapy while enhancing efficacy relative to interferon-based therapy. DAAs are broadly categorized into the NS3/4A protease inhibitors, NS5A inhibitors, and the non-nucleoside and nucleotide NS5B inhibitors. Ribavirin, […]

Quick Hits

Evidence from a few randomized trials and multiple observational studies supports performing a liver ultrasound every six months as part of hepatocellular carcinoma (HCC) surveillance in patients with hepatitis C virus-related cirrhosis (HCVc). Although the possibility of using other technical modalities is tempting, there are concerns regarding radiation exposure and cost. Use of multiphase computed […]

Quick Hits

The availability of highly efficacious and tolerable all-oral direct acting antiviral (DAA) regimens for the treatment of chronic hepatitis C virus (HCV) infection in 2014 was met with a mix of joy and relief among both HCV providers and chronically infected patients. Finally we could do away with the low cure rates and toxicities associated […]

Quick Hits

The hepatitis C virus is primed to develop resistance to direct acting antiviral drugs (DAAs). This stems from several aspects of HCV biology including an extraordinary rate of viral turnover in infected individuals and the error-prone nature of the viral RNA dependent RNA polymerase. Assumptions based on these characteristics led to modeling studies that predicted […]

Quick Hits

The patient was a 55-year-old, young grandmother who said, I’ve tried them all, as I reviewed her HCV treatment history, which included interferon (IFN), pegylated IFN, consensus IFN and now maintenance IFN. She pulled up her pant legs and said, My real problem is here. Her lower legs had hyperpigmentation on them but no obvious […]